Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib
JCO Precision Oncology · 2024
DOI: 10.1200/po.24.00303 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Lilie L Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Phthalazines, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE We tested the ability of [ 18 F] fluorthanatrace (FTT), a radiolabeled analog of poly(ADP-ribose) polymerase (PARP)-1 inhibitors, to demonstrate target engagement on positron emission tomography (PET) scans from patients with newly diagnosed primary breast cancer receiving the PARP inhibitor (PARPi) talazoparib. METHODS Seven patients with germline BRCA1/2 pathogenic variants underwent [ 18 F]FTT PET-computed tomography scanning at baseline, and five underwent repeat scanning 14 days after talazoparib initiation. Maximum uptake on PET was quantified in the primary tumor, involved nodes, contralateral pectoralis muscle, and lumbar vertebra body level 3, and compared between the two time points. RESULTS Blocking of [ 18 F]FTT was observed on the second scan. Potentially strong but nonsignificant correlations were found between changes in tumor volume (on ultrasound at 1 month v baseline) and percentage changes in tumor-to-muscle uptake ratio at 14 days from baseline (Spearman rank correlation coefficient r = 1; P = .083); and between the highest-grade hematologic toxicity and baseline bone marrow-to-muscle (B/M) uptake ratio ( r = 0.72; P = .068) and percentage change in B/M ratio at 14 days from baseline ( r = 0.87; P = .058). CONCLUSION We conclude that [ 18 F]FTT can image target engagement by PARPi, but larger studies are needed to determine whether [ 18 F]FTT uptake can predict response to PARPi and whether uptake of [ 18 F]FTT in bone marrow may be an early predictor of hematologic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX.
- Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Lilie L Lin, Ruitao Lin, Timothy Yap, Jennifer K Litton
Förderung
- NCI NIH HHS
Zitieren
APA
Lin, L. L., Wong, F., Lin, R., Yap, T., & Litton, J. K. (2024). Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib. JCO Precision Oncology. https://doi.org/10.1200/po.24.00303
Vancouver
Lin LL, Wong F, Lin R, Yap T, Litton JK. Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib. JCO Precision Oncology. 2024. doi:10.1200/po.24.00303
BibTeX
@article{Lin2024,
author = {Lin, Lilie L and Wong, Franklin and Lin, Ruitao and Yap, Timothy and Litton, Jennifer K},
title = {Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.24.00303}
}
EUVIMED